Om

SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing therapies for difficult-to-treat fungal infections. Its current portfolio centers on antifungal medicines designed to address conditions such as vulvovaginal candidiasis, recurrent vulvovaginal candidiasis, invasive candidiasis, and other serious invasive fungal diseases. The company’s marketed product, BREXAFEMME, is used in women’s health and infectious disease settings, while its research pipeline includes additional antifungal candidates such as SCY-247 aimed at broader systemic infections. SCYNEXIS’s work is concentrated on novel triterpenoid-based antifungal science, positioning it within the specialized anti-infective segment of the pharmaceutical market. Headquartered in Jersey City, New Jersey, SCYNEXIS serves a niche but important role in addressing infections where existing treatment options can be limited by resistance, tolerability, or disease severity.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I SCYNEXIS MED ENDAVU: Køb SCYNEXIS ($135) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i SCYNEXIS, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.